Indication
In adults for treatment of neovascular (wet) age-related macular degeneration (nAMD)
Medicine details
- Medicine name:
- bevacizumab gamma (Lytenava)
- SMC ID:
- SMC2744
- Pharmaceutical company
- Outlook Therapeutics Ltd
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Publication due date:
- TBC